Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ...

Healthcare lobbying hit record highs in 2025 as drugmakers, hospitals, and insurers pushed back against the government moves ...

Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated a Buy rating on Pfizer Inc. (NYSE:PFE) on December 17 and set a price ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 16, Pfizer Inc. (NYSE:PFE) said the next few years are expected to be bumpy, starting in 2026.

American pharma giant Pfizer (PFE) leads the pack as pharmaceutical companies plan price increases for at least 350 branded medications, according to data seen by Reuters. The move underscores the ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an analysis of PFE stock now.

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the launch of Viagra (sildenafil), CEO Albert Bourla said at the 44th Annual ...

In the latest close session, Pfizer (PFE) was up +1.12% at $25.18. The stock outpaced the S&P 500's daily gain of 0.19%. Meanwhile, the Dow experienced a rise of 0.66%, and the technology-dominated ...

Madrigal Pharma is reheating a drug for metabolic dysfunction-associated steatohepatitis (MASH) put on ice by Pfizer, hoping to build on its first-mover advantage in therapies for the widespread liver ...

BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to ...